Table II.
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
|
|
|||||
Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
Age >60 years | 1.07 | 0.67–1.72 | 0.771 | |||
Male gender | 0.76 | 0.52–1.11 | 0.153 | |||
ECOG score ≥2 | 2.77 | 1.99–3.86 | <0.001 | 3.49 | 2.20–5.54 | <0.001 |
Stages III/IV | 1.76 | 1.15–2.70 | 0.010 | |||
Extranodal involvement >1 | 0.93 | 0.65–1.31 | 0.666 | 0.51 | 0.31–0.85 | 0.001 |
Positive B symptomsa | 2.12 | 1.55–2.91 | <0.001 | 1.67 | 1.12–2.50 | 0.012 |
Bone marrow involvement | 0.53 | 0.40–0.71 | <0.001 | 0.39 | 0.26–0.61 | <0.001 |
LDH level >ULN | 2.00 | 1.49–2.68 | <0.001 | 2.07 | 1.40–3.06 | <0.001 |
β2-MG level >ULN | 2.19 | 1.60–3.00 | <0.001 | |||
IPI >2 | 2.08 | 1.48–2.92 | <0.001 |
B symptoms: fever, night sweats or weight loss.
ECOG, Eastern Cooperative Oncology Group; LDH lactate dehydrogenase; β2-MG, β2-microglobulin; IPI, International Prognostic Index; ULN, upper limit of normal; HR, hazard ratio; CI, confidence interval.